COPD in 2016: some answers, more questions

The Lancet Respiratory Medicine

Volumn 4, Issue 12, 2016, Pages 941-943

  Labaki, Wassim W ^a   Martinez, Carlos H ^a   Han, MeiLan K ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; FLUTICASONE PROPIONATE PLUS SALMETEROL; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; MUSCARINIC RECEPTOR BLOCKING AGENT;

CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE EXACERBATION; EOSINOPHIL COUNT; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INCIDENCE; LUNG FUNCTION; MEDICATION COMPLIANCE; MORBIDITY; MORTALITY; NOTE; POPULATION RESEARCH; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SPIROMETRY; TREATMENT OUTCOME; WALKING; COMBINATION DRUG THERAPY; EARLY DIAGNOSIS; PATHOPHYSIOLOGY; VITAL CAPACITY;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; EARLY DIAGNOSIS; FORCED EXPIRATORY VOLUME; HUMANS; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; VITAL CAPACITY;

EID: 84996920952     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(16)30324-1     Document Type: Note

References (9)

1. 1 Adeloye, D, Chua, S, Lee, C, et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health, 5, 2015, 020415.
2. 2 Lozano, R, Naghavi, M, Foreman, K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2095–2128.
3. 3 US Preventive Services Task Force (USPSTF). Screening for chronic obstructive pulmonary disease: US Preventive Services Task Force Recommendation Statement. JAMA 315 (2016), 1372–1377.
4. 4 Vestbo, J, Hurd, SS, Agusti, AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 187 (2013), 347–365.
5. 5 Woodruff, PG, Barr, RG, Bleecker, E, et al. Clinical significance of symptoms in smokers with preserved pulmonary function. N Engl J Med 374 (2016), 1811–1821.
6. 6 Dransfield, MT, Kunisaki, KM, Strand, MJ, et al. Acute exacerbations and lung function loss in smokers with and without COPD. Am J Respir Crit Care Med, 2016, 10.1164/rccm.201605-1014OC published online Aug 24.
7. 7 Wedzicha, JA, Banerji, D, Chapman, KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med 374 (2016), 2222–2234.
8. 8 Vestbo, J, Anderson, JA, Brook, RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet 387 (2016), 1817–1826.
9. 9 Vestbo, J, Leather, D, Diar Bakerly, N, et al. Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice. N Engl J Med 375 (2016), 1253–1260.